12:00 AM
 | 
Mar 05, 2001
 |  BioCentury  |  Emerging Company Profile

Novazyme: Getting the translation right

The point of doing targeted therapy is that it generally requires a smaller amount of medication compared to systemic therapy, which relies on diffusion of drug to the site of action. Novazyme Inc. is trying to address the lysosomal storage diseases by using its glycobiology technology to target needed enzymes to their sites of action. By targeting the products, Novazyme hopes to reduce the amount of enzyme required and reduce side effects.

There are 49 lysosomal storage diseases, including Pompe's disease, the Mucopolysaccharidoses (MPS) I-IV, Gaucher disease, and Fabry disease. All of the diseases are inherited as either autosomal recessive traits or as X-chromosome-linked traits.

In general, the lysosomal storage diseases involve the lack of an enzyme needed to break down a particular carbohydrate or lipid product within lysosomes. Because the...

Read the full 642 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >